Depression in brain tumor patients-early detection and screening.
Brain tumor
Depression
Glioblastoma
Neuropsychological screening
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
16 May 2023
16 May 2023
Historique:
received:
12
01
2023
accepted:
27
04
2023
medline:
18
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
Depres sion is reported in up to 90% of cancer patients but to this date, a standardized screening tool for depression specifically modified for patients diagnosed with brain tumors is lacking. Thus, this study aims to develop an adapted screening tool and identify a suitable time slot for screening. Sixty-one patients with brain lesions were interviewed prior to neurosurgical resection. For screening purposes, established depression scores were used. A study-specific questionnaire (SSQ) was developed based on patient interviews prior to the trial. Two subgroups were analyzed: patients with benign and patients with malignant tumors (including brain metastases). As a subgroup within malignant lesions, patients with glioblastoma (GBM) were also analyzed separately. Of patients, 87.5% with GBM presented with results > 16 points on the Center for Epidemiologic Studies Depression Scale (CES-D) after surgery. A decline in patients with benign brain tumors (p = 0.0058) and an increase in patients with malignant tumors (p = 0.0491) could be shown over time for CES-D scores. In this study, we established a new prototype screening tool for depression. In patients diagnosed with GBM, the number of patients needed to screen for identification of symptoms of depression was 1.59. Best time for screening was 35 days after surgery. Considering the high prevalence and low number needed to screen of depression in patients diagnosed with GBM, we strongly encourage their routine screening during follow-up appointments (35 days after surgery). We encourage a plan to further establish the questionnaire developed in this pilot study.
Sections du résumé
BACKGROUND
BACKGROUND
Depres sion is reported in up to 90% of cancer patients but to this date, a standardized screening tool for depression specifically modified for patients diagnosed with brain tumors is lacking. Thus, this study aims to develop an adapted screening tool and identify a suitable time slot for screening.
METHODS
METHODS
Sixty-one patients with brain lesions were interviewed prior to neurosurgical resection. For screening purposes, established depression scores were used. A study-specific questionnaire (SSQ) was developed based on patient interviews prior to the trial. Two subgroups were analyzed: patients with benign and patients with malignant tumors (including brain metastases). As a subgroup within malignant lesions, patients with glioblastoma (GBM) were also analyzed separately.
RESULTS
RESULTS
Of patients, 87.5% with GBM presented with results > 16 points on the Center for Epidemiologic Studies Depression Scale (CES-D) after surgery. A decline in patients with benign brain tumors (p = 0.0058) and an increase in patients with malignant tumors (p = 0.0491) could be shown over time for CES-D scores. In this study, we established a new prototype screening tool for depression. In patients diagnosed with GBM, the number of patients needed to screen for identification of symptoms of depression was 1.59. Best time for screening was 35 days after surgery.
CONCLUSIONS
CONCLUSIONS
Considering the high prevalence and low number needed to screen of depression in patients diagnosed with GBM, we strongly encourage their routine screening during follow-up appointments (35 days after surgery). We encourage a plan to further establish the questionnaire developed in this pilot study.
Identifiants
pubmed: 37191815
doi: 10.1007/s00520-023-07785-5
pii: 10.1007/s00520-023-07785-5
pmc: PMC10188424
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
339Informations de copyright
© 2023. The Author(s).
Références
J Natl Cancer Inst Monogr. 2004;(32):57-71
pubmed: 15263042
Int Rev Psychiatry. 2014 Feb;26(1):16-30
pubmed: 24716498
Neurosurg Rev. 2020 Apr;43(2):497-511
pubmed: 30094499
Psychooncology. 1999 Jul-Aug;8(4):315-33
pubmed: 10474850
Ann N Y Acad Sci. 2015 May;1345:25-35
pubmed: 25809518
PLoS One. 2016 May 16;11(5):e0155431
pubmed: 27182821
Dement Geriatr Cogn Disord. 2015;40(5-6):311-39
pubmed: 26360014
J Natl Cancer Inst. 2011 Jan 5;103(1):61-76
pubmed: 21106962
J Affect Disord. 2017 Oct 15;221:36-46
pubmed: 28628766
J Clin Oncol. 2011 Feb 1;29(4):413-20
pubmed: 21149651
Br J Neurosurg. 1999 Oct;13(5):480-5
pubmed: 10627779
Arch Intern Med. 2003 Nov 10;163(20):2433-45
pubmed: 14609780
Eur J Cancer Care (Engl). 2019 Jan;28(1):e12410
pubmed: 26531122
Eur Arch Psychiatry Clin Neurosci. 2006 Dec;256(8):516-21
pubmed: 16960653
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945
Br J Psychiatry. 2007 Apr;190:326-32
pubmed: 17401039
West J Nurs Res. 2016 Jul;38(7):893-908
pubmed: 26902798
Neurosurgery. 2004 Feb;54(2):358-66; discussion 366-7
pubmed: 14744282